Anti-Parkinsonian Activity of Mushrooms Against Orofacial Dyskinesia Induced by Reserpine in Wistar Rats

Abstract

A neurological ailment called Parkinson’s disease (PD) which distresses roughly 1.5% of people above age 65 in the world. Dopamine nerve cell death (DA) in the Substantia nigra parc compacta (SNc) with the development of a striatal DA deficiency are two features of PD.As of now, the focalization of PD is uncertain. The goal was to assess the neuroprotective efficacy of ethanolic extracts from different mushroom species viz. P. ostreatus, A. bisporus and C. cibarius are against orofacial dyskinesia (OD) by reserpine and their in vivo antioxidant status. In this study, reserpine (1-mg/kg) was repeatedly administered on alternate days over a five-day interval to produce vacuous chewing movements (VCMs) and tongue protrusions (TPs) in rats. Evaluation of reserpine-induced catalepsy was done. Catalase (CAT), glutathione reductase (GSH), superoxide dismutase (SOD) and lipid peroxidation (LPO) concentrations were examined in prosencephalon in response to an ethanolic extract of mushrooms. The histological evaluation of attenuating oxidative stress also shows the effectiveness of all these mushroom extracts. In animal models of Parkinson’s disease produced by reserpine, P. ostreatus, A. bisporus and C. cibarius were found to have a therapeutic impact against the disease.